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Abstract
Background: Fine needle aspiration biopsy (FNAB) is an accurate test commonly used to determine whether
thyroid nodules are malignant in adults. However, less is known about its diagnostic accuracy for this purpose in
children, where conduct of FNAB is less frequent, more technically challenging, and pre-test probabilities of
malignancy are often higher. The purpose of this systematic review is to evaluate the diagnostic accuracy of FNAB
for the detection of malignancy in pediatric thyroid nodules.
Methods: We will search electronic bibliographic databases (MEDLINE, EMBASE, the Cochrane Library, and
Evidence-Based Medicine) from their date of inception, reference lists of included articles, proceedings from
relevant conferences, and the table of contents of the Journal of Pediatric Surgery (January 2007–present). Two
reviewers will independently screen titles and abstracts and identify diagnostic accuracy studies involving FNAB of
the thyroid in children. We will include studies comparing FNAB to a reference standard of surgical histopathology
or clinical follow-up for detection of malignancy in pediatric thyroid nodules. Two investigators will independently
extract data and assess risk of bias using the Quality of Diagnostic Accuracy Studies-II tool. Pooled estimates of
sensitivity, specificity, and positive and negative likelihood ratios will be calculated using bivariate random-effects
and hierarchical summary receiver operating characteristic models. In the presence of between-study heterogeneity,
we will conduct stratified meta-analyses and meta-regression to determine whether diagnostic accuracy estimates
vary by country of origin, use of ultrasound guidance during FNAB, qualifications of the individuals performing/
interpreting FNAB, adherence to the Bethesda criteria for cytology classification, length of clinical follow-up, timing
of data collection, patient selection methods, and presence of verification bias.
Discussion: This meta-analysis will determine the diagnostic accuracy of FNAB for detection of malignancy in
pediatric thyroid nodules and explore whether heterogeneity observed across studies may be explained by
variations in patient population, FNAB technique or interpretation, and/or study-level risks of bias. This will be the
first study to determine the accuracy of Bethesda cytological classification levels of FNAB (benign, atypical, follicular,
suspicious, malignant). We expect that our results will help in guiding clinical decision-making in children with
thyroid nodules.
Systematic review registration: PROSPERO No. CRD42014007140
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Background
Thyroid nodules are uncommon in children, with a preva-
lence ranging from 0.05 to 2% [1–6]. Nodules are more
likely to be found in girls than boys and in adolescents
compared to their younger counterparts [7, 8]. Although
nodules have a low risk of malignant transformation in
adults (5 to 15%), the incidence in pediatric patients is es-
timated to be as high as 70% [2, 5, 7, 9]. Risk factors for
thyroid malignancy in children include family history of
thyroid cancer, certain genetic mutations, and exposure to
therapeutic or environmental irradiation.
Some authors have advocated that the increased ma-
lignant potential of thyroid nodules in children justifies
the liberal use of surgical exploration in several pediatric
populations [5]. However, although thyroid surgery is
typically well-tolerated, the potential for associated
complications deters many clinicians from proceeding
directly to operation [10–12]. Risks of thyroid surgery
include hypothyroidism, hypoparathyroidism, recurrent
laryngeal nerve injury, and postoperative bleeding and
infection. These risks increase during completion thyroid-
ectomy if a malignancy is found after hemithyroidectomy
[13]. Thus, an accurate diagnostic test is essential to fa-
cilitate pre-operative decisions regarding management
of pediatric thyroid nodules.
Fine needle aspiration biopsy (FNAB), also known as fine
needle aspiration cytology, has been used since the early
1980s to classify the cytology of (and thereby diagnose)
suspicious superficial soft tissue lesions. Improvements
in ultrasound (US) technology have led to increased de-
tection of incidental thyroid nodules and, consequently,
more frequent use of FNAB [14]. A generalist (family
practitioner, pediatrician, or internist) or a specialist
(endocrinologist, surgeon, radiologist, or pathologist)
may perform this procedure, with or without US guidance
(which, in theory, may lead to heightened accuracy and
increased safety). As comfort levels with FNAB have in-
creased, greater confidence in the accuracy of cytology
results has reduced the number of thyroid surgeries for
benign nodules [15–17]. However, most diagnostic ac-
curacy studies of FNAB for prediction of malignancy in
thyroid nodules have focused on adult subjects, leading
pediatric clinicians to question whether its reported accur-
acy is generalizable to children [18–20].
In 2007, the Thyroid FNAB State of the Science Con-
ference addressed the varying terminology in FNAB
reporting, concluding that inconsistencies prevented
comparisons of diagnoses across different sites. Prior
to the conference, most pathologists classified FNAB
cytology as inadequate, benign, malignant, or indeterminate
using variable definitions. Discussions at this conference
resulted in the publication of the Bethesda System for
Reporting Thyroid Cytopathology (also known as the
Bethesda criteria) in 2009. The Bethesda criteria classify
FNAB samples as non-diagnostic, benign, atypia/follicular
lesion of undetermined significance, follicular neoplasm
or suspicious for follicular neoplasm, suspicious for
malignancy, or malignant [21]. The largest benefit of
these criteria is that they clearly describe and link
each of these categories to a risk of malignancy, fa-
cilitating prognostication and clinical decision-making
regarding surgery or non-operative/conservative manage-
ment [22]. After introduction of this classification
scheme, the American Thyroid Association endorsed
FNAB as the standard of care in North America for
evaluation of thyroid nodules in their clinical practice
guidelines [23].
Although a meta-analysis was published in 2009
evaluating the accuracy of FNAB for detection of ma-
lignancy in pediatric thyroid nodules, another system-
atic review is urgently required for several reasons
[24]. First, multiple relevant articles have been pub-
lished since the last review by Stevens et al. [24], po-
tentially altering conclusions of the study. Second,
their meta-analysis reviewed literature published prior
to January 2007 (that is, before introduction of the Be-
thesda criteria) and included minimal data on the use of US
guidance during FNAB. Third, Stevens et al. [24] did not
directly address the risk of design-related biases among
the included articles—biases that have previously been
shown to overestimate the reported accuracy of a
diagnostic test—potentially limiting or even prevent-
ing clinical application of their findings [24–26]. In
particular, as clinicians may elect to follow patients
clinically rather than proceed to thyroid surgery after
a non-malignant FNAB result, this will prevent com-
parison against the gold standard of surgical histo-
pathology. Thus, partial verification bias is expected to
be a major limiting factor in pediatric FNAB diagnos-
tic accuracy studies. As the previous study did not as-
sess these potential sources of bias and heterogeneity,
an updated and more elaborate systematic review and
meta-analysis could verify or potentially refute the ap-
plicability of their findings to current pediatric clinical
practices. The objective of this study is to systematically
review the diagnostic accuracy of FNAB for the detec-
tion of thyroid malignancy.
Methods
Protocol
This study adopts recommendations on the conduct and
reporting of systematic reviews and meta-analyses out-
lined by the Preferred Reporting Items in Systematic Re-
views and Meta-Analyses statement, the Meta-Analysis
of Observational Studies in Epidemiology proposal, and
the Cochrane Diagnostic Test Accuracy Working Group
[27–30]. The protocol is registered in the PROSPERO
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International Prospective Register of Systematic Reviews
(Registration No. CRD42014007140).
Focused clinical question
In pediatric patients with a thyroid nodule, is FNAB as
accurate as surgical histopathology or clinical follow-up
for the detection of thyroid malignancy?
PICOD components
 Population
 Patients ≤18 years of age, or those defined as
exclusively pediatric patients by the authors, with
a thyroid nodule that is palpable or seen on
diagnostic imaging
 Intervention
 FNAB of the thyroid nodule, with or without US
guidance
 Comparison
 Surgical histopathology or clinical follow-up
 Outcome
 Test accuracy for detection of thyroid malignancy
as defined by the authors, including true and false
positives and negatives, sensitivity and specificity,
and positive and negative likelihood ratios
 Design
 Diagnostic accuracy studies [30]
Primary outcome
 Test accuracy of FNAB for as defined by the authors
Secondary outcomes
 Test accuracy of FNAB for classification of lesions
according to the Bethesda criteria (non-diagnostic,
benign, atypia/follicular lesion of undetermined
significance, follicular neoplasm or suspicious for
follicular neoplasm, suspicious for malignancy,
malignant). This outcome was chosen as secondary
instead of primary to allow for a comprehensive
evaluation of the accuracy of FNAB for classifying
thyroid nodules in children (according to both
Bethesda and non-Bethesda criteria)
 Test accuracy of FNAB with or without US
guidance for detection of thyroid malignancy
Search strategy
We will search Ovid MEDLINE and EMBASE, the
Cochrane Database of Systematic Reviews, and Evidence-
Based Medicine from their date of first inception, without
language, publication date, or other restrictions. PubMed
will also be searched to capture articles not yet indexed in
MEDLINE. We will also use the PubMed “related articles”
feature for articles included in the systematic review and
manually search the table of contents for the Journal of
Pediatric Surgery from January 2007 onward. To identify
unpublished and/or ongoing studies, we will contact
experts in the field and search clinical trials registries
(ClinicalTrials.gov and Current Controlled Trials), refer-
ence lists of included articles, and conference proceedings
of major pediatric surgery (American Pediatric Surgical
Association, Canadian Association of Pediatric Sur-
geons, and Pacific Association of Pediatric Surgeons)
and pediatric endocrinology (European Society for
Pediatric Endocrinology and Pediatric Endocrine Soci-
ety/Lawson Wilkins Pediatric Endocrine Society) meet-
ings from 2007 to 2015.
With the assistance of an information scientist/medical
librarian, we developed search filters encompassing the
themes thyroid, biopsy, and pediatrics, using a combin-
ation of keywords and Medical Subject Heading (MeSH)/
Emtree terms (Table 1). These three themes will be
combined in MEDLINE and EMBASE using the Boolean
operator “AND.” A diagnostic accuracy theme will not be
used as it has been shown to potentially lead to the exclu-
sion of relevant articles in systematic reviews of diagnostic
accuracy studies [30–32]. A similar search strategy using
themes and Boolean operators will be performed in
remaining databases.
Inclusion and exclusion criteria
After removing duplicate citations, two investigators (SWL,
KYW) will independently screen all remaining titles
and abstracts in duplicate. This initial screen will be
broad intentionally to avoid missing potentially relevant
citations. We will subsequently review the full text of any
citations that appear to satisfy the following criteria:
 Patients ≤18 years of age or described to be pediatric
by the author(s)
 FNAB performed on the thyroid
Those articles identified for full text review will subse-
quently be read independently in full by the same two
investigators (SWL, KYW) to determine their eligibility
for inclusion in the systematic review. We will use the
following inclusion/exclusion criteria based on PICOD:
Inclusion criteria
 Population
 The study population consisted of patients
≤18 years of age (or patient populations where
the study authors did not provide summary
estimates describing age, but did report that the
included patients were exclusively children), with
a thyroid nodule that is palpable or seen on
diagnostic imaging
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 Data for at least ten pediatric patients were
reported (to exclude case reports and small case
series)
 Intervention
 The index test was FNAB of a thyroid nodule,
with or without US guidance
 Comparison
 The reference standard was surgical
histopathology or clinical follow-up
 Outcome
 The studies examined test accuracy for detection
of thyroid malignancy as defined by the authors,
including true and false positives and negatives,
sensitivity and specificity, and positive and
negative likelihood ratios
 Sufficient data were presented to tabulate the
results comparing FNAB to surgical pathology or
clinical follow-up into two-by-two contingency
tables (Fig. 1)
 Design
 Diagnostic accuracy studies (single gated) that
compare the results of an index test to the results of
a reference standard on the same subjects [33–35]
Exclusion criteria
 Non original data
 Duplicate data sets
 Overlapping data sets
 Articles with smaller cohorts will be excluded
Table 1 Electronic database search strategies
Ovid MEDLINE, Cochrane Database of Systematic Reviews,




MeSH terms Text words Emtree terms Text words
Thyroid Thyroid gland, thyroid nodule,
thyroid neoplasm,
Thyroid* Thyroid gland, thyroid nodule, thyroid tumor, thyroid
carcinoma, thyroid cancer
Thyroid*
Biopsy Biopsy; biopsy, fine-needle;
biopsy, needle; image-guided





Needle biopsy, biopsy, image guided biopsy, biopsy
needle, large core needle biopsy, tumor biopsy,
biopsy technique, fine biopsy needle, core biopsy




Pediatric Pediatrics, adolescent, child Adol*, child*, ped*,
paed*
Pediatrics, adolescent, child Adol*, child* ped*
paed*
MeSH medical subject headings
Fig. 1 Two-by-two table examining the primary outcome. Definitions of true and false positives and negatives comparing fine needle aspiration
biopsy (FNAB) to the final diagnosis based on surgical histopathology or non-surgical clinical follow-up. Positive and negative results of index test
(FNAB) separated into non-benign and benign. Positive and negative results of reference test (surgical histopathology or non-surgical clinical
follow-up) separated into malignant and non-malignant. TN true negative, FN false negative, FP false positive, TP true positive, FNAB fine needle
aspiration biopsy
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 Authors will be contacted to clarify their
patient population if the degree of overlap is
unclear
 Non-human studies
 Studies involving patients with exclusively
malignant or benign thyroid surgical
histopathology
Two investigators (SWL, KYW) will pilot test inclu-
sion and exclusion criteria using 20 randomly selected
articles to ensure complete investigator agreement of
the criteria. Agreement regarding inclusion and exclu-
sion of full-text articles between the two investigators
(SWL, KYW) will be quantified using the kappa statis-
tic. A kappa statistic greater than 0.6 will be consid-
ered moderate agreement [36]. Disagreements will be
resolved by consensus or arbitration by a third party
(DJR or DMR) after the article of interest has been re-
read in full by all investigators [37].
Data extraction
Two investigators (SWL, KYW) will extract data from all
eligible diagnostic studies independently and in duplicate
using a predesigned Microsoft Access 2010 (Microsoft,
Redmond, WA) database form. This database form will
be pilot tested on a random sample of five included
studies until reliable data extraction is confirmed (kappa





 Year of publication
2. Study design and methodology
 Directionality of data collection
 Retrospective, prospective
 Participant selection method
 Consecutive, random
 Inclusion and exclusion criteria
 Including whether thyroid surgery was listed
as a prerequisite for enrolment
 Study setting
 Country of origin, single versus multi-site




4. Experimental (index) test (FNAB)
 FNAB description
 Number of biopsies, complications, use of US
guidance, qualifications of the individual




 Adherence to Bethesda or other criteria,
qualifications of pathologist reporting results
(pathologist, cytopathologist, pediatric
pathologist, pediatric cytopathologist)
5. Reference standard test
 Type of surgery performed (total thyroidectomy,
hemithyroidectomy, surgical biopsy)
 Length of time between FNAB and surgery
 Results of surgical histopathology (benign versus
malignant, type of malignancy)
 Qualifications of pathologist reporting results
(pathologist, pediatric pathologist)
 Number of patients who did not proceed from
FNAB to surgery
 Length and type of follow-up (clinical, radiological)
 Number of patients lost to follow-up
6. Blinding of the pathologists to the results of FNAB
and surgical histopathology
7. Study results and analysis
 Data to populate a two-by-two table (Fig. 1) to
assess the primary outcome for FNAB
 Figure 1 defines true and false positives and
negatives based on the two-by-two table. Positive
and negative results of index test (FNAB) will be
separated into benign and non-benign. Positive
and negative results of gold standard reference
test (surgical histopathology) and surrogate
reference test (clinical follow-up) will be
separated into malignant and non-malignant.
 This table will be used to generate pooled
estimates of diagnostic accuracy (sensitivity,
specificity, positive and negative likelihood
ratios) as our primary outcome
 For our secondary outcome analysis, where
possible, we will extract data to populate six-by-six
tables (Fig. 2) to assess the accuracy of FNAB using
the six Bethesda classifications (non-diagnostic,
benign, atypia/follicular lesion of undetermined
significance, follicular neoplasm or suspicious for
follicular neoplasm, suspicious for malignancy,
malignant), compared with six potential outcomes:
four surgical (benign, follicular adenoma,
follicular thyroid carcinoma, other malignancy),
and two non-operative (clinical follow-up, loss to
follow-up).
 To evaluate the test accuracy of each FNAB
diagnostic category to predict malignancy, the
six-by-six data will be condensed into multiple
two-by-two contingency tables by altering the
threshold of interpretation of FNAB results as
test negative or positive. Figure 3 shows the
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sliding thresholds used for FNAB interpretation,
stratified into four separate comparisons. All
non-diagnostic biopsies will be removed from
the diagnostic accuracy meta-analysis as initial
and final diagnosis of malignant or
non-malignant disease is unclear in patients
clinically followed or lost to follow-up
 Figure 4 defines true and false positives and
negatives based on the sliding thresholds for
all four comparisons. Positive and negative
results of the gold standard reference test
(surgical histopathology) will be separated
into malignant and non-malignant. Positive
and negative results of the surrogate refer-
ence test (clinical follow-up) will be sepa-
rated into final diagnoses based on FNAB
results. We will assume that non-malignant
FNAB would be followed clinically and con-
verted to surgical management if malignancy
developed. Positive and negative results of pa-
tients lost to follow-up will be separated into
final diagnoses based on the assumption that
non-malignant FNAB would be followed clinic-
ally and that malignant FNAB lost to follow-up
would subsequently be managed at a different
facility
 These tables will be used to generate multiple
pooled estimates of diagnostic accuracy
(sensitivity, specificity, positive and negative
likelihood ratios) for each comparison
Non-English language literature will be translated by
interpreters. Agreement between the two investigators
(SWL, KYW) will be ensured by consensus or arbitration
by a third party (DJR or DMR) as needed.
Study quality assessment and risk of bias
The risk of bias of each article will be evaluated inde-
pendently by two investigators (SWL, KYW) and reported
according to the Quality Assessment of Diagnostic Ac-
curacy Studies (QUADAS-2) tool [38]. The presence
of spectrum, threshold, disease progression, and verifi-
cation bias (partial or differential) will be specifically
assessed, as defined below.
Spectrum bias occurs when study participants do not
represent the population of interest due to inappropriate
patient selection. This is an anticipated source of bias in
articles where thyroid surgery forms part of the inclusion
criteria. These exclusively surgical cohorts likely represent
a distinct subset of the population with more worrisome
findings and a higher pre-test probability for malignancy,
leading to potential differences in diagnostic accuracy
Fig. 2 Six-by-six table examining the secondary outcome in studies that report data using the Bethesda criteria. FNAB fine needle aspiration biopsy
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results. Another example of spectrum bias includes
studies targeting hypothyroid or hyperthyroid patients
specifically, where extrapolation to the general pediatric
population with thyroid nodules may be inappropriate.
Threshold bias develops when pathologists use varying
definitions to report FNAB results. This leads to a greater
likelihood to diagnose benign or malignant disease based
on an individual pathologist’s threshold of concern. The
Bethesda criteria were introduced to standardize FNAB
classification and minimize threshold bias. Studies report-
ing results by Bethesda versus other criteria will be com-
pared to evaluate the potential contribution of threshold
bias to diagnostic accuracy.
Disease progression bias is a concern when the interval
between the index test and reference standard is long
enough to potentially allow progression of disease from
benign to malignant or from one type of malignant disease
to another. An index test may be negative and the refer-
ence test positive due to rapid development of malignancy,
rather than signify an inaccurate index test. To assess the
risk of disease progression bias, an appropriate time frame
between FNAB and surgery and length of clinical follow-
up would need to be defined. However, this interval is not
well described in the literature as the latency period for
development of thyroid malignancy after discovery of a
nodule may extend for years, despite exposure to known
Fig. 3 Sliding thresholds. Sliding thresholds used for fine needle aspiration biopsy (FNAB) interpretation as test negative or positive. Four separate
comparisons (A, B, C, D) evaluate the test accuracy of each FNAB diagnostic category to predict thyroid nodule malignancy. FNAB fine needle
aspiration biopsy
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risk factors [39, 40]. As such, we will collect data regarding
these parameters without imposing predefined intervals
such that studies may later be categorized into those
with shorter versus longer intervals for stratified meta-
regression.
Partial verification bias occurs when results of the
index test influence whether or not the patient receives
the reference standard. There is significant potential for
this type of bias among the studies that will be included
in this systematic review as benign cytology may de-
crease the likelihood of any type of follow-up, whether
surgical or clinical, unless there are other significant risk
factors for malignancy. Partial verification bias frequently
leads to inflated diagnostic accuracy as benign FNAB re-
sults may be assumed inappropriately to represent true
negative disease [41]. Differential verification bias arises
when results of the index test determine which reference
standard is used to confirm the diagnosis. Using clinical
follow-up as a surrogate reference standard, many studies
will be prone to differential verification bias with benign
cytology followed clinically instead of with surgery. Verifi-
cation bias, whether partial or differential, is expected to
be the primary limiting factor affecting the validity of
pooled estimates across the diagnostic accuracy studies
that will be included in this systematic review. In order to
eliminate verification bias, in an ideal diagnostic accuracy
Fig. 4 Definitions of true and false positives and negatives. Definitions of true and false positives and negatives after condensing six-by-six tables
into two-by-two contingency tables for comparisons (a–d). In a, positive and negative results of index test (fine needle aspiration biopsy [FNAB])
separated into non-benign and benign. In b, positive results of FNAB including follicular neoplasm, suspicious for malignancy and malignant, and
negative results of FNAB including benign and atypia/follicular lesion. In c, positive results of FNAB including suspicious for malignancy and malignant,
and negative results of FNAB including benign, atypia/follicular lesion and follicular neoplasm. In d, positive results of FNAB including malignant only,
and negative results of FNAB including benign, atypia/follicular lesion, follicular neoplasm and suspicious for malignancy. In all comparisons, positive
and negative results of gold standard reference test (surgical histopathology) separated into malignant and non-malignant. Positive and negative
results of surrogate reference test (clinical follow-up) and losses to follow-up separated into final diagnoses based on FNAB results. Non-diagnostic
biopsies were removed from analysis as final diagnosis of malignant or non-malignant disease unclear in patients lost to follow-up. TN true negative,
FN false negative, FP false positive, TP true positive, FNAB fine needle aspiration biopsy
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study, all patients presenting with a nodule must undergo
both FNAB and surgical excision to definitively diagnosis
benign or malignant disease. However, this practice does
not occur as most low-risk patients are observed in
follow-up to avoid the risks of surgery. Ethically, inclusion
of patients with FNAB who undergo surgery and lifelong
clinical follow-up provides the best case scenario for
confirming diagnostic accuracy. Verification bias may
be reduced, but not eliminated, with serial clinical and
radiological examinations for several years to capture
any false negative FNAB, though the required duration of
follow-up is unclear. It is anticipated that this systematic
review will find a mixture of studies with different biases.
The interconnectedness of spectrum and verification bias
in this setting will also be assessed, since studies with
surgical cohorts prone to spectrum bias are also at low
risk of verification bias (i.e., all patients will have definitive
surgical histopathology).
As a supplement to the QUADAS-2 tool, we will also
examine the timing of data collection (prospective,
retrospective), the qualifications of the individual per-
forming the FNAB (general practitioner, pediatrician,
endocrinologist, surgeon, radiologist, pathologist) or the
interpreting pathologist (general pathologist, cytopatholo-
gist, pediatric pathologist, pediatric cytopathologist), and
adherence of cytology reporting to the Bethesda versus
other criteria.
Disagreements between the two investigators (SWL,
KYW) will be resolved by consensus or arbitration by a
third party (DJR or DMR).
Data synthesis and analysis
True and false positives and negatives will be defined by
two-by-two contingency tables (Fig. 1) for the primary
outcome. True and false positives and negatives will be
defined after condensing six-by-six tables (Fig. 2) into
two-by-two contingency tables (Fig. 4) for the secondary
outcome that will examine each Bethesda classification
level. These tables will be used to calculate study-level
estimates of sensitivity, specificity, and positive and
negative likelihood ratios for detection of thyroid malig-
nancy. Hierarchical summary receiver operating character-
istic (HSROC) curves will be generated to depict the
bivariate relationship between individual study estimates
of sensitivity and specificity [30, 42, 43]. We will also use
this model to calculate the proportion of between-study
heterogeneity that may be due to diagnostic threshold
variability using the between-study covariance parameter
[30, 43–45].
Bivariate random-effects models will be used to derive
pooled estimates of sensitivity, specificity, and positive and
negative likelihood ratios for detection of malignancy with
FNAB [43, 45, 46]. These models incorporate the degree
of negative correlation that may exist between sensitivity
and specificity across studies [43, 45, 46]. This joint
synthesis of diagnostic accuracy estimates is unbiased
despite diagnostic threshold variability and facilitates
the development of Bayesian probability modifying and
Fagan plots [42, 43, 45–47]. These two plots will allow for
an assessment of the likely post-test probability obtained
after applying FNAB to samples of patients with varying
ranges of pre-test probabilities of thyroid malignancy.
These models will also allow us to determine the extent of
heterogeneity (due to diagnostic threshold variability or
study-level covariates) in our pooled estimates through
the production of forest plots and the computation of
I2- and Q-statistics [45–49].
In the presence of inter-study heterogeneity, we will
use the bivariate model to conduct subgroup analyses
and meta-regression to determine whether a number of
pre-defined covariates may explain variation in reported
diagnostic performance results across studies [43–46,
48–50]. Covariates of interest will include those describ-
ing the study setting (country of origin, single versus
multi-site), risk of bias (prospective versus retrospective
data collection, random versus consecutive method of
selection, thyroidectomy as part of the inclusion criteria,
presence of verification bias, length of follow-up, loss to
follow-up greater than 15 %), FNAB implementation and
interpretation (use of US guidance, qualifications of indi-
vidual performing and interpreting FNAB, use of Bethesda
or other criteria), and length of clinical follow-up. We will
also examine whether any studies exert undue influence
on our pooled diagnostic accuracy estimates by perform-
ing a sensitivity analysis, removing those that appear to be
influential outliers or those which may include potentially
overlapping patients. Influential studies will be identified
using spike plots of Cook’s distance and scatter plots of
standardized residuals [42, 43, 51–53]. Finally, to assess
for the presence of small study effects potentially due
to publication bias, we will create funnel plots using
the diagnostic odds ratio and conduct Deek’s asymmetry
tests [54].
All statistical analyses will be performed using Stata
version 13.1 (Stata Corp, College Station, TX), including
the “midas” and “metandi” command packages [42, 43, 55].
Discussion
Thyroid nodules can provoke anxiety in children, fam-
ilies, and physicians alike due to diagnostic uncertainty
in the setting of greater potential for malignancy. The
ability of a diagnostic test to distinguish malignant from
benign disease is paramount for clinicians to provide ap-
propriate counselling regarding treatment and prognos-
tication. In addition to providing a systematic review
and meta-analysis of the diagnostic accuracy of FNAB in
pediatric thyroid nodules for the detection of malig-
nancy, this will be the first study to determine the
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accuracy of FNAB according to the Bethesda criteria. In
doing this, our results may serve as a better guide for
clinical decision-making in children with thyroid
nodules.
Although the American Thyroid Association endorses
FNAB as the standard of care in North America for the
evaluation of thyroid nodules in adults and children, the
evidence supporting this recommendation is likely based
on the results of studies conducted among adults.
Pediatric studies may be limited by several study-level
biases. Thus, this systematic review and meta-analysis
will rigorously examine the potential magnitude of influ-
ence that individual study-level biases may have on the
diagnostic accuracy of FNAB. Other specific aims to be
addressed by this study include determining the value of
adherence to the Bethesda criteria, US guidance, and the
qualifications of the individual performing and interpret-
ing the FNAB on the diagnostic accuracy of FNAB. If
these factors are found to enhance diagnostic accuracy,
this may support the need for routine referral of children
with thyroid nodules to specialty centres where US and
FNAB-trained personnel are available to improve patient
care and outcomes.
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